Rheumatoid Arthritis - Drug Pipeline Analysis and Market Forecasts to 2015

Oct. 8, 2010 - PRLog -- GlobalData, the industry analysis specialist, has released a new report on the Pharmaceutical and Healthcare industry, "Rheumatoid Arthritis-Drug Pipeline Analysis and Market Forecasts to 2015". The report is an essential source of information and analysis on the global Rheumatoid Arthritis (RA) market. The report identifies the key trends shaping and driving the global RA market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global RA sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

-Annualized global rheumatoid arthritis market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes CD targetters, THF dehydrogenase targetters, TNF targetters, COX targetters, Interleukin targetters, kinase targetters, and Cytokine targetters other than TNF.
-Analysis of the current and future market competition in the global rheumatoid arthritis market. Key market players covered are Pfizer Inc., Roche, Biogen Idec, Amgen Inc. and Mitsubishi Tanabe Pharma.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with rheumatoid arthritis.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global rheumatoid arthritis market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global rheumatoid arthritis market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global rheumatoid arthritis market landscape?-Identify, understand and capitalize.



Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Rheumatoid Arthritis Market: Market Characterization 6
2.1 Overview 6
2.2 Rheumatoid Arthritis Market Size 6
2.3 Rheumatoid Arthritis Market Forecast and CAGR 6
2.4 Drivers and Barriers for Rheumatoid Arthritis Market 7
2.4.1 Drivers for Rheumatoid Arthritis Market 7
2.4.2 Barriers for Rheumatoid Arthritis Market 7
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Rheumatoid Arthritis Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profile for the Major Marketed Products in Rheumatoid Arthritis Market 11
3.3.1 Enbrel (etanercept) 11
3.3.2 Humira (adalimumab) 12
3.3.3 Remicade (infliximab) 13
3.3.4 Rituxan (rituximab) 14
3.3.5 Celebrex (celecoxib) 14
3.4 Product Profile for the Major Marketed Products in Rheumatoid Arthritis Market 15
3.4.1 Enbrel (etanercept) 15
3.4.2 Humira (adalimumab) 16
3.4.3 Remicade (infliximab) 17
3.4.4 Rituxan (rituximab) 17
3.4.5 Celebrex (celecoxib) 18
3.5 Key Takeaway 19
4 Rheumatoid Arthritis Market: Pipeline Assessment 20
4.1 Overview 20
4.2 Strategic Pipeline Assessment 20
4.2.1 Technology Trends Analytic Framework 20  
4.3 Rheumatoid Arthritis Therapeutic-Promising Drugs under Clinical Development 22
4.4 Molecule Profile for Promising Drugs under Clinical Development for Rheumatoid Arthritis 23
4.4.1 T-614 (iguratimod) 23
4.4.2 CP-690550 24
4.4.3 Ocrelizumab (Humanized Anti-CD20 mAb) 24
4.4.4 Arzerra (HuMax-CD20 /Ofatumumab) 25
4.4.5 PN 400 (VIMOVO) 25
4.5 Rheumatoid Arthritis Therapeutics Market-Clinical Pipeline by Mechanism of Action 26
4.6 Rheumatoid Arthritis Pipeline-Pipeline by Clinical Phases of Development 27
4.6.1 Rheumatoid Arthritis Therapeutics-Regulatory and Phase III Clinical Pipeline 28
4.6.2 Rheumatoid Arthritis Therapeutics-Phase II Clinical Pipeline 30
4.6.3 Rheumatoid Arthritis Therapeutics-Phase I Clinical Pipeline 34
4.6.4 Rheumatoid Arthritis Therapeutics-Preclinical Pipeline 36
4.6.5 Rheumatoid Arthritis Therapeutics-Discovery Pipeline 37
4.7 Discontinued/Suspended Drugs for Rheumatoid Arthritis 38
4.8 Key Takeaway 38
5 Rheumatoid Arthritis Market: Implications for Future Market Competition 39
6 Rheumatoid Arthritis Market: Future Players in the Rheumatoid Arthritis  Market 41
6.1 Introduction 41
6.2 Pfizer 41
6.2.1 Overview 41
6.2.2 Autoimmune and Musculoskeletal Portfolio 42
6.2.3 Rheumatoid Arthritis Product Portfolio 42
6.3 Roche 43
6.3.1 Overview 43
6.3.2 Autoimmune and Musculoskeletal Portfolio 44
6.3.3 Rheumatoid Arthritis Product Portfolio 44
6.4 Amgen 45
6.4.1 Overview 45
6.4.2 Autoimmune and Musculoskeletal Portfolio 45
6.4.3 Rheumatoid Arthritis Product Portfolio 46
6.5 Biogen idec 46
6.5.1 Overview 46
6.5.2 Autoimmune and Musculoskeletal Portfolio 46
6.5.3 Rheumatoid Arthritis Product Portfolio 47
6.6 Mitsubishi Tanabe 48
6.6.1 Overview 48
6.6.2 Autoimmune and Musculoskeletal Portfolio 48
6.6.3 Rheumatoid Arthritis Product Portfolio 49
7 Rheumatoid Arthritis Market: Appendix 50
7.1 Market Definitions 50
7.2 Abbreviations 50
7.3 Research Methodology 51
7.3.1 Coverage 51
7.3.2 Secondary Research 52
7.3.3 Forecasting 52
7.3.4 Primary Research 54
7.3.5 Expert Panels Validation 55
7.4 Contact Us 55
7.5 Disclaimer 55
7.6 Sources 55

List of Tables
1.1 List of Tables
Table 1:  Global Rheumatoid Arthritis Therapeutics Market, Revenue ($bn), 2000-2008 7
Table 2:  Global Rheumatoid Arthritis Therapeutics Market, Revenue ($bn), 2009-2015 7
Table 3:   Major Marketed Products Comparison in  Rheumatoid Arthritis  Market, 2009 19
Table 4:  Rheumatoid Arthritis Therapeutics-Most Promising Drugs under Clinical Development, 2009 22
Table 5:  Rheumatoid Arthritis Therapeutics-Regulatory and Phase III Clinical Pipeline, 2009 28
......

List of Figures
1.2 List of Figures
Figure 1:  Global Rheumatoid Arthritis Market Revenue ($m), 2000-2015 6
Figure 2:  Opportunity and Unmet Need in the Rheumatoid Arthritis Market,2009 9
Figure 3:  Strategic Competitor Assessment of the Major Marketed Products in Rheumatoid Arthritis, 2009 11
Figure 4:  Technology Trends Analytic Framework of the Rheumatoid Arthritis  Pipeline, 2009 21
Figure 5:  Technology Trends Analytic Framework of the Rheumatoid Arthritis  Pipeline-Description, 2009 22
......

# # #

ChinaCCM.com is China's leading industry consultancy expert offering industry intelligence and research solution, ChinaCCM Market Research Centre is a research division focusing on professional market survey and industry research.